Enterprise Value

115.5B

Cash

5.524B

Avg Qtr Burn

N/A

Short % of Float

1.71%

Insider Ownership

0.11%

Institutional Own.

87.85%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tecartus® (brexucabtagene autoleucel) (CAR-T) Details
B-cell acute lymphoblastic leukemia, Acute lymphoblastic leukemia, Leukemia

Approved

Quarterly sales

Yescarta® Details
B-cell lymphoma, Lymphopenia

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Trodelvy® (sacituzumab govitecan-hziy) Details
Breast cancer, ER+/HER2- breast cancer, Cancer

Approved

Quarterly sales

Biktarvy Details
Human immunodeficiency virus

Approved

Quarterly sales

Seladelpar (MBX-8025) Details
Primary biliary cholangitis, Non-alcoholic steatohepatitis , Primary sclerosing cholangitis, Liver disease

PDUFA

Approval decision

Lenacapavir Details
Human immunodeficiency virus

Phase 3

Data readout

Phase 3

Update

Phase 3

Update

Anito-cel Details
Multiple myeloma

Phase 3

Initiation

Sunlenca (Lenacapavir) Details
Human immunodeficiency virus

Phase 2/3

Data readout

Phase 2b

Update

Phase 2

Data readout

Etrumadenant Details
Colorectal cancer

Phase 2

Update

Phase 2

Update

Yescarta Details
Lymphopenia, B-cell lymphoma

Phase 2

Update

Magrolimab+Azacitidine Details
High risk myelodysplastic syndromes

Failed

Discontinued